Latest news

View all

Finland – April 23, 2025

Record funding for Finnish bioimaging

Euro-BioImaging Finland, the research infrastructure of Finnish bioimaging, has received funding of about EUR 28 million from the Research Council of Finland.

Intellectual Property – April 23, 2025

SynAct Pharma receives Notice of Allowance for grant of US patent

The Unites States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application with claims covering a method of treating rheumatoid arthritis (RA) with resomelagon (AP1189) in combination with methotrexate (MTX).

Biotech Business – April 22, 2025

Zelluna reaches milestone – Manufacturing process established

Zelluna has developed, scaled and automated its manufacturing process for its TCR-NK cell therapies.

Acquisition – April 22, 2025

KKR makes SEK 11.6 billion bid for Biotage

RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, has announced a recommended public tender offer to the shareholders of Biotage to transfer all of the ordinary shares of Biotage to RWK BidCo for SEK 145 in cash per ordinary share.

Biotech article – April 21, 2025

Oncopeptides announces new RWD data

Oncopeptides has announced the publication of new real-world data (RWD) that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM).

Business article – April 21, 2025

Global health & Local efforts: Opening up the market of biosimilars

“To be able to control costs and serve patients, the world will need biosimilars,” says Róbert Wessman, Icelandic businessman and entrepreneur.

Advertisement

14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • Global health & Local efforts: We take a closer look at some of our most urgent global health challenges and what is being accomplished here in the Nordics.
  • Exclusive interview: Our profile duo in this issue is Sirpa and Markku Jalkanen. They share a passion for immunology and have both clearly made their marks in research, business, and academia
  • Hot topics: Learn more about manufacturing T-cell therapies at scale, get the CDMOs’ perspectives on mechanisms for coping with uncertainty, and stay updated on the changing US regulatory environment.
  • Careers: Interested in a career path within sales? Charlotte Schönbeck, Getinge, and Hamid Parsa, Cambrex, share their journeys and best advice.
Subscribe now

Opinion & debate

Clinical Trials

Clinical Trials – April 13, 2025

Orexo and Abera Bioscience announce positive data

The companies have announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences entered in December 2024. The aim of the collaboration is to develop mucosal vaccines by combining Orexo’s powder-based drug delivery technology AmorphOX with Abera’s […]

Clinical Trials – April 9, 2025

New clinical trial map launched in the EU

A new clinical trial map is now accessible from the public website of the Clinical Trials Information System (CTIS).

Clinical Trials – March 25, 2025

Immunovia provides further positive data from the VERIFI study

Immunovia has announced additional results from the VERIFI study of its next-generation pancreatic cancer test, strengthening the company’s position as it prepares to launch the pancreatic cancer blood test commercially. 

Clinical Trials – March 18, 2025

Oncorena receives FDA approval to initiate studies in the US

The FDA has approved the company’s IND application to initiate the Phase I/II study Oncorella-1.

Clinical Trials – March 17, 2025

Anocca to start first in-human trial in advanced pancreatic cancer

The company has announced the authorization of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European Union’s (EU) harmonised framework, for VIDAR-1, with Germany acting as the reference state.

Clinical Trials – February 28, 2025

Evaxion extends phase 2 trial with personalized cancer vaccine

Evaxion Biotech will further enhance the data package from its ongoing phase 2 trial with the company’s lead asset EVX-01 by extending the trial from two to three years.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Business article – April 7, 2025

Global health & Local efforts: New hope in the neurodegenerative disease pipeline 

Even though many have tried and few succeeded in the quest to find viable treatments for neurodegenerative diseases, Nordic drug developers continue to take different approaches to crack the riddle.

Commentary – December 11, 2024

AI and the 2024 Nobel Prizes: A Revolutionary Moment for Life Sciences

The 2024 Nobel Prizes in Chemistry and Physics reflect the revolutionary impact of artificial intelligence (AI) on life sciences. These awards, celebrating advancements in protein design and neural networks, demonstrate how AI is transforming how we approach drug discovery, personalized medicine, and healthcare management.

Profiles in Science – June 24, 2024

Exclusive interview: Jens Juul Holst

His is not a household name, but the drugs developed thanks to Danish scientist Jens Juul Holst’s research certainly are.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Advertisement

Explore topics

Job opportunities

View more

Ascendis Pharma

Sr. Manager / Associate Director Competitive Intelligence

Ascendis Pharma A/S, a U.S. publicly held, Biopharmaceutical company founded in Copenhagen, Denmark in 2007, committed to addressing unmet medical needs within the therapeutic area’s endocrinology and oncology.

Argon Medical Devices

Clinical Specialist Germany

ARGON Medical Devices is a global manufacturer of specialty medical products, headquartered in Plano, Texas. The company offers a broad range of medical devices for Interventional Radiology, Vascular Surgery, Interventional Cardiology and Oncology.

Bioneer

Senior Business Development Manager CDMO

Bioneer is a trusted strategic partner for Biotech and Pharmaceutical companies worldwide. With 40 years of experience, they drive impact in the Life Science ecosystem across the Nordics and globally as a Danish government-approved Research and Technology Organization (RTO).

Orifarm

Director, Supplier Relationship Management

In Orifarm, they aim to bring healthy days by making modern healthcare a better deal for the people and the societies they serve. Everyone should have access to modern medicine.

Bioneer

Senior Business Development Manager In Vitro Modelling

Bioneer is a trusted strategic partner for Biotech and Pharmaceutical companies worldwide. With 40 years of experience, they drive impact in the Life Science ecosystem across the Nordics and globally as a Danish government-approved Research and Technology Organization (RTO).

Stryker

Territory Sales Manager, Surgical Technologies

As Territory Sales Manager, you will help us deliver on our mission of making healthcare better by promoting and selling Stryker’s Surgical Technologies product portfolio.

Advertisement

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.